Skip to content

Cytokinetics CYTK Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-605.1%+90.4pp-695.4%-38.5pp-656.9%-19.0pp-638%+2,305pp-2,943.3%-40.6pp
Net margin-784%+108pp-891.6%-29.4pp-862.2%-155pp-707.2%+2,494pp-3,201.5%-10.4pp
Efficiency
Asset turnover0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.0×
Liquidity
Current ratio4.2×-0.3×4.5×-2.3×6.9×+0.1×6.8×+0.8×-0.2×
Per Share
Book value per share-$6.71-22.1%-$5.49-26.5%-$4.34-40.7%-$3.09-37.3%-$2.25-86.0%
Valuation
Market capitalization$8.12B+4.5%$7.77B+18.1%$6.58B+64.9%$3.99B-16.2%$4.76B-14.3%
Price / sales76.7×-11.5×88.2×+12.8×75.4×+28.9×46.5×-201×247.6×-52.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Cytokinetics's ratios come from?
Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.